other material
confidence high
sentiment positive
materiality 0.90
Praxis Precision Medicines announces positive topline results from EMBOLD study of relutrigine in SCN2A/SCN8A DEE
Praxis Precision Medicines, Inc.
- Placebo-adjusted reduction of 46% in countable motor seizures for relutrigine-treated patients.
- 5 of 16 randomized patients achieved 28-day seizure-free status on relutrigine vs. none on placebo.
- Relutrigine was generally safe and well tolerated; no patients discontinued due to adverse events.
- Eight patients completed ≥1 OLE period with median motor seizure reduction of 75%.